

**Supplementary Table 3. New Melanoma Patient Demographics**

| <b>PATIENT<br/>NUMBER</b> | <b>AGE AT<br/>DRAW</b> | <b>GENDER</b> | <b>RACE<sup>1</sup></b> | <b>30 DAYS<br/>PRIOR TREATMENT<sup>2</sup></b>                                                                              |
|---------------------------|------------------------|---------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| 1                         | 60                     | FEMALE        | C                       | NONE                                                                                                                        |
| 2                         | 44                     | MALE          | C                       | HD Interferon alpha-2b<br>subcutaneous phase w/<br>significant toxicity<br>Oral Temodar prior, but on hold<br>for 2-3 weeks |
| 3                         | 74                     | FEMALE        | C                       |                                                                                                                             |
| 4                         | 81                     | MALE          | C                       | Synthroid 112 mcg, Nexium                                                                                                   |
| 5                         | 55                     | MALE          | C                       | NONE                                                                                                                        |

<sup>1</sup> C = Caucasian

<sup>2</sup> HD = High dose